The first product candidate from the MPP technology, Inveltys (1% solution of a topical corticosteroid, loteprednol etabonate, LE) was approved by the FDA to treat pain and inflammation after eye surgery in 2018. Sales are growing 30% quarterly per the recent Q3 earnings call. Peak sales estimate for the drug is approx. $300M.
seekingalpha.com/article/...ead-of-stride-3-data-this-quarter
kalarx.com/pipeline/
old.nasdaq.com/de/symbol/kala/real-time
seekingalpha.com/article/...ead-of-stride-3-data-this-quarter
kalarx.com/pipeline/
old.nasdaq.com/de/symbol/kala/real-time